

**FEDERAL RESERVE SYSTEM****Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 8, 2004.

**A. Federal Reserve Bank of New York** (Jay Bernstein, Bank Supervision Officer) 33 Liberty Street, New York, New York 10045-0001:

1. *Community Bank System, Inc.*, Dewitt, New York; to engage *de novo* through its subsidiary Benefit Plans Administrative Services, Inc., Utica, New York, in employee benefits consulting and incidental activities, pursuant to section 225.28(b)(9)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, September 17, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04-21363 Filed 9-22-04; 8:45 am]

**BILLING CODE 6210-01-S**

**FEDERAL RESERVE SYSTEM****Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 8, 2004.

**A. Federal Reserve Bank of New York** (Jay Bernstein, Bank Supervision Officer) 33 Liberty Street, New York, New York 10045-0001:

1. *Community Bank System, Inc.*, Dewitt, New York; to engage *de novo* through its subsidiary Benefit Plans Administrative Services, Inc., Utica, New York, in employee benefits consulting and incidental activities, pursuant to section 225.28(b)(9)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, September 20, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04-21405 Filed 9-22-04; 8:45 am]

**BILLING CODE 6210-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Agency for Healthcare Research and Quality****Agency Information Collection Activities: Proposed Collection; Comment Request**

**AGENCY:** Agency for Healthcare Research and Quality, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request the Office of Management and Budget (OMB) to allow the proposed information collection project:

“Voluntary Customer Surveys Generic Clearance for the Agency for Healthcare Research and Quality” (formerly known as Voluntary Customer Satisfaction Survey Generic Clearance for the Agency for Healthcare Research and Quality). In accordance with the Paperwork Reduction Act of 1995, 44 U.S.C. 3506(c)(2)(A), AHRQ invites the public to comment on this proposed information collection request to allow AHRQ to conduct customers surveys.

This proposed information collection was previously published in the **Federal Register** on July 13, 2004 and allowed 60 Days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 Days for public comment.

**DATES:** Comments on this notice must be received by October 25, 2004.

**ADDRESSES:** Written comments should be submitted to: John Kraemer, at the Office of Information and Regulatory Affairs, OMB at the following e-mail address [John\\_Kraemer@omb.eop.gov](mailto:John_Kraemer@omb.eop.gov) and the fax number is (202) 395-6974.

**FOR FURTHER INFORMATION CONTACT:** Cynthia D. McMichael, AHRQ, Reports Clearance Officer, (301) 427-1651.

**SUPPLEMENTARY INFORMATION:****Proposed Project**

“Voluntary Customer Surveys Generic Clearance for the Agency for Healthcare Research and Quality.”

In response to Executive Order 12862, the Agency for Healthcare Research and Quality (AHRQ) plans to conduct voluntary customer surveys to assess strengths and weaknesses in agency program services. Customer surveys to be conducted by AHRQ may include readership surveys from individuals using AHRQ automated and electronic technology databases to determine satisfaction with the information provided or surveys to assess effect of the grants streamlining efforts.

Results of these surveys will be used in future program planning initiatives and to redirect resources and efforts, as needed, to improve AHRQ program services. The current clearance will expire September 30, 2004. This is a request for a generic approval from

OMB to conduct customer surveys over the next three years.

#### Method of Collection

The data will be collected using a combination of methodologies appropriate to each survey. These methodologies include:

- Evaluation forms;
- Mail surveys;
- Focus groups;
- Automated and electronic technology (e.g., e-mail, Web-based surveys, instant fax, AHRQ Publications Clearinghouse customer feedback) and,
- Telephone surveys.

#### ESTIMATED ANNUAL RESPONDENT BURDEN

| Type of Survey               | No. of respondents | Average burden/response | Total hours of burden |
|------------------------------|--------------------|-------------------------|-----------------------|
| Mail/telephone surveys ..... | 51,200             | .15                     | 7,680                 |
| Automated/Web-based .....    | 52,000             | D.163                   | 8,476                 |
| Focus groups .....           | 200                | 1.0                     | 200                   |
| Totals .....                 | 103,400            | NA                      | 16,356                |

#### Request for Comments

In accordance with the above cited Paperwork Reduction Act legislation, comments on the AHRQ's information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of functions of AHRQ, including whether the information will have practical utility; (b) the accuracy of the Agency's estimate of the burden (including hours and costs) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Dated: September 16, 2004.

**Carolyn M. Clancy,**  
Director.

[FR Doc. 04-21339 Filed 9-22-04; 8:45 am]

BILLING CODE 4160-90-M

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. 2004N-0408]

#### Regulatory Site Visit Training Program

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration's (FDA's) Center for

Biologics Evaluation and Research (CBER) is announcing the initiation of a Regulatory Site Visit Training Program. This program is intended to give CBER's regulatory review staff, compliance staff, and other relevant staff an opportunity to visit biologics facilities. The visit is intended to provide first hand experience to CBER staff and to give a better understanding of the biologics industry, including its challenges and its operations. The purpose of this notice is to invite biologics companies interested in participating in this program to contact CBER for more information.

**DATES:** Submit a written or electronic requests for participation in this program by October 25, 2004.

**ADDRESSES:** If your biologics facility is interested in offering a site visit or learning more about this training opportunity for CBER staff, you should submit a request to participate in this program to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic requests to <http://www.fda.gov/dockets/ecomments>.

#### FOR FURTHER INFORMATION CONTACT:

Lonnie Warren-Myers, Division of Manufacturers Assistance and Training, Center for Biologics Evaluation and Research (HFM-49), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-2000, FAX: 301-827-3079, e-mail: [cbertrainingsuggestions@cber.fda.gov](mailto:cbertrainingsuggestions@cber.fda.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

CBER regulates biological products including blood and blood products, vaccines, and cellular and gene therapies. CBER is committed to

advancing the public health through innovative regulations that help ensure the safety, effectiveness, and timely delivery to patients of biological products. CBER has initiated various training and development programs to promote high performance of its regulatory review staff, compliance staff, and other relevant CBER staff. CBER seeks to continuously enhance and update review efficiency and quality as well as the quality of its regulatory efforts and interactions. CBER is initiating the Regulatory Site Visit Training Program to provide CBER staff the opportunity to visit biologics facilities to observe first-hand the industry's biologic development and manufacturing processes and thereby obtain better understanding of the biologics industry and its operations.

Further, this program is intended to improve CBER's understanding of current practices, regulatory impacts and needs, and improve communication between CBER staff and industry. The first phase of the program will focus on blood, plasma, and fractionation industries including transfusion centers, although other industries may be considered including vaccines, cellular and gene therapy, and tissues.

#### II. The Regulatory Site Visit Training Program

##### A. Regulatory Site Visits

In this program, over a period of time to be agreed upon with the biologics facility, small groups (five or less) of CBER staff may observe operations of biologics manufacturing, packaging, pathology/toxicology laboratory testing, and regulatory affairs operations. These visits, or any part of the program, are not intended as a mechanism to inspect, assess, judge, or perform a regulatory enforcement function, but are meant to improve mutual understanding and to